A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
InventisBio Co., Ltd
Study ID
NCT07489885
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • D-2570 Tablet — DRUG
    Active Treatment
  • Placebo Tablets — DRUG
    Identical Tablet

Study Details

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Key Dates

Start date
Jun 3, 2026
Status verified
Mar 2026
Primary completion
Aug 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: D-2570 low dose
    Low dose of D-2570
  • Active Comparator: D-2570 High Dose
    medium dose level of D-2570
  • Placebo Comparator: Placebo
    Placebo arm

Primary Outcome Measure

Improvement in PASI-90 [ Time Frame: Assessment completed after 12 weeks of treatment/placebo ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Study CenterBirminghamAlabama35244
Kathryn Stazzone
[email protected]
302-519-5966
Study CenterChula VistaCalifornia91910
Kathryn Stazzone
[email protected]
302-519-5966

Find similar trials in Birmingham, AL

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Study Center· Birmingham, ALStudy Center· Chula Vista, CA

Related Studies